Telix Pharmaceuticals 2022 JP Morgan Healthcare Conference Presentation

Telix Pharmaceuticals presented its precision oncology radiopharmaceutical portfolio at the JP Morgan Virtual Healthcare Conference in January 2022. The company highlighted FDA approval for Illuccix (TLX591-CDx) for prostate cancer imaging, alongside its extensive global distribution network reaching 80 countries and active clinical programs across 8 indications.